• Ameri A (1999). The effects of cannabinoids on the brain.Prog Neurobiol58: 315–348.

  Article CAS  Google Scholar 

• Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos Net al (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types.J Neurosci25: 6845–6856.

  Article CAS  Google Scholar 

• Ceccarini J, De Hert M, van Winkel R, Koethe D, Bormans G, Leweke Met al (2010).In vivo PET imaging of cerebral type 1 cannabinoid receptor availability in patients with schizophrenia.Schizophrenia Res117: 170.

  Article  Google Scholar 

• Chavarría-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori Aet al (2008). Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.Am J Med Genet B Neuropsychiatr Genet147: 279–284.

  Article  Google Scholar 

• Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, Chen CH (2008). Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex.Int J Neuropsychopharmacol11: 207–216.

  Article CAS  Google Scholar 

• Cohen J (1988).Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates: Hillsdale, New Jersey.

  Google Scholar 

• Dalton VS, Wang H, Zavitsanou K (2009). HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat.Neurochem Res34: 1343–1353.

  Article CAS  Google Scholar 

• De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia.Lipids Health Dis2: 5.

  Article  Google Scholar 

• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.Neuroscience103: 9–15.

  Article CAS  Google Scholar 

• Deng C, Han M, Huang X-F (2007). No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.Neurosci Bull23: 341–347.

  Article CAS  Google Scholar 

• D’Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies.Eur Arch Psychiatry Clin Neurosci259: 413–431.

  Article  Google Scholar 

• Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.Arch Gen Psychiatry65: 772–784.

  Article  Google Scholar 

• Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis.Cereb Cortex17: 175–191.

  Article  Google Scholar 

• Eggan SM, Stoyak SR, Verrico CD, Lewis DA (2010). Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.Neuropsychopharmacology35: 2060–2071.

  Article CAS  Google Scholar 

• Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber Jet al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.Neuropsychopharmacology29: 2108–2114.

  Article CAS  Google Scholar 

• Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain.Neuroscience77: 299–318.

  Article CAS  Google Scholar 

• Harper CG, Kril JJ, Daly JM (1988). Brain shrinkage in alcoholics is not caused by changes in hydration: a pathological study.J Neurol Neurosurg Psychiatry51: 124–127.

  Article CAS  Google Scholar 

• Harrison PJ, Laatikainen LM, Tunbridge EM, Eastwood SL (2010). Human brain weight is correlated with expression of the ‘housekeeping genes’ beta-2-microglobulin (beta2M) and TATA-binding protein (TBP).Neuropathol Appl Neurobiol36: 498–504.

  Article CAS  Google Scholar 

• Hill C, Keks NA, Roberts S, Opeskin K, Dean B, MacKinnon Aet al (1996). Problem of diagnosis in postmortem brain studies of schizophrenia.Am J Psychiatry153: 533–537.

  Article CAS  Google Scholar 

• Keks NA, Hill C, Roberts S, Dean B, Opeskin K, MacKinnon Aet al (1997). Diagnostic instrument for brain studies (DIBS).Schizophrenia Res24: 34.

  Article  Google Scholar 

• Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu Fet al (2011). Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.J Clin Psychopharmacol31: 86–91.

  Article CAS  Google Scholar 

• Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FMet al (2007). Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.J Neural Transm114: 1055–1063.

  Article CAS  Google Scholar 

• Kozlovsky N, Weickert CS, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G (2004). Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients.J Neural Transm111: 1583–1592.

  Article CAS  Google Scholar 

• Leweke FM, Koethe D, Pahlisch F, Schreiber D, Gerth CW, Nolden BMet al (2009). Antipsychotic effects of cannabidiol.Eur Psychiatry24 (Suppl 1): 207.

  Article  Google Scholar 

• Liu Q-R, Pan C-H, Hishimoto A, Li C-Y, Xi Z-X, Llorente-Berzal Aet al (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.Genes Brain Behav8: 519–530.

  Article CAS  Google Scholar 

• Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe Met al (2008). Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.J Neurosci28: 2976–2990.

  Article  Google Scholar 

• Mato S, Pazos A (2004). Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain.Neuropharmacology46: 716–726.

  Article CAS  Google Scholar 

• McGlashan TH, Fenton WS (1991). Classical subtypes for schizophrenia: literature review for DSM-IV.Schizophr Bull17: 609–632.

  Article CAS  Google Scholar 

• Meltzer HY, Arvanitis L, Bauer D, Rein W (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.Am J Psychiatry161: 975–984.

  Article  Google Scholar 

• Newell KA, Deng C, Huang X-F (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.Exp Brain Res172: 556–560.

  Article CAS  Google Scholar 

• Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: (delta)9-tetrahydrocannabinol, cannabidiol and (delta)9-tetrahydrocannabivarin.Br J Pharmacol153: 199–215.

  Article CAS  Google Scholar 

• Onaivi ES, Ishiguro H, Gong J-P, Patel S, Perchuk A, Meozzi PAet al (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.Ann N Y Acad Sci1074: 514–536.

  Article CAS  Google Scholar 

• Rajkowska G, Goldman-Rakic PS (1995). Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria.Cereb Cortex5: 307–322.

  Article CAS  Google Scholar 

• Roberts S, Hill C, Dean B, Keks NA, Opeskin K Copolov D (1998). Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience.Aust NZ J Psych32: 73–76.

  Article CAS  Google Scholar 

• Roser P, Vollenweider FX, Kawohl W (2010). Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.World J Biol Psychiatry11 (2 Part 2): 208–219.

  Article  Google Scholar 

• Secher A, Husum H, Holst B, Egerod KL, Mellerup E (2010). Risperidone treatment increases CB1 receptor binding in rat brain.Neuroendocrinology91: 155–168.

  Article CAS  Google Scholar 

• Sundram S, Copolov D, Dean B (2005). Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.Naunyn Schmiedebergs Arch Pharmacol371: 428–433.

  Article CAS  Google Scholar 

• Sundqvist N, Garrick T, Bishop I, Harper C (2008). Reliability of post-mortem psychiatric diagnosis for neuroscience research.Aust N Z J Psychiatry42: 221–227.

  Article  Google Scholar 

• Thacore VR, Shukla SR (1976). Cannabis psychosis and paranoid schizophrenia.Arch Gen Psychiatry33: 383–386.

  Article CAS  Google Scholar 

• Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt Het al (2007). No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.Pharmacogenomics J7: 275–281.

  Article CAS  Google Scholar 

• Ugur T, Bartels M, Kis B, Scherbaum N (2008). Psychosis following anti-obesity treatment with rimonabant.Obes Facts1: 103–105.

  Article CAS  Google Scholar 

• Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó Vet al (2009). Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.Psychopharmacology (Berl)206: 313–324.

  Article  Google Scholar 

• Villares J (2007). Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain.Neuroscience145: 323–334.

  Article CAS  Google Scholar 

• Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick Tet al (2010). Selection of reference gene expression in a schizophrenia brain cohort.Aust N Z J Psychiatry44: 59–70.

  Article  Google Scholar 

• Weston-Green K, Huang XF, Han M, Deng C (2008). The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain.Int J Neuropsychopharmacol11: 827–835.

  Article CAS  Google Scholar 

• Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE, Sim-Selley LJ (2008). Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling andin vivo pharmacology in rats.Neuropharmacology55: 1183–1190.

  Article CAS  Google Scholar 

• Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara Met al (2010a). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.Neuroimage52: 1505–1513.

  Article CAS  Google Scholar 

• Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS (2010b). Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia.Neuroscience169: 1071–1084.

  Article CAS  Google Scholar 

• Yang Y, Fung SJ, Rothwell A, Tianmei S, Weickert CS (2010). Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia.Biol Psychiatry69: 63–70.

  Article  Google Scholar 

• Zalewski C, Johnson-Selfridge MT, Ohriner S, Zarrella K, Seltzer JC (1998). A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients.Schizophr Bull24: 127–145.

  Article CAS  Google Scholar 

• Zavitsanou K, Garrick T, Huang X-F (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry28: 355–360.

  Article CAS  Google Scholar 

• Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.Braz J Med Biol Res39: 421–429.

  Article CAS  Google Scholar 

• Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol.J Clin Psychiatry56: 485–486.

  CAS PubMed  Google Scholar 

Download references